INOVIO PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
INO$1.45-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| For the Year ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net loss | $(135,117,352) | $(279,818,065) | $(303,658,710) |
| Other comprehensive loss: | |||
| Foreign currency translation | (3,920) | (25,556) | (30,134) |
| Unrealized (loss) gain on short-term investments, net of tax | 40,060 | (390,949) | 4,048 |
| Comprehensive loss | $(135,081,212) | $(280,234,570) | $(303,684,796) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.